Search Results - db4axx

14 Results

Sort By:

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors

The invention relates to compounds that inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5’-triphosphate (dNTP) as substrate and like many other enzymes, the reaction is reversible. Pyrophosphate analogs like imidodiphosphate strongly promote reverse reaction dNTP products containing...

Published: 7/25/2024 | Inventor(s): William (Bill) Beard, David Shock, Samuel Wilson

Keywords(s): DB4AXX, HIV-1, INHIBITING, PYROPHOSPHATE, TRANSCRIPTASE, VLXXXX, YBXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples

One of the problems with the development of current therapies for HIV infection is that the virus rapidly develops resistance to drugs such as reverse transcriptase (RT) inhibitors. CDC researchers have developed an enzyme-based methodology for detecting phenotypic resistance to antiretroviral drugs whose mode of action decreases the efficiency of...

Published: 7/25/2024 | Inventor(s): Gerardo Lerma, Shinji Yamamoto, William Switzer, Thomas Folks, Walid Heneine

Keywords(s): ANTIVIRAL, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, DB4AXX, DETECTING, DRUGS, DXXXXX, KIT, Method, OID-NCHHSTP-DHPSE, Resistance, VLXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Occupational Safety and Health, TherapeuticArea > Cardiology, Application > Diagnostics, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Therapeutics

Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics

This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased...

Published: 7/25/2024 | Inventor(s): James Barry, Darin Knaus, Edward Moynihan, Eric Friets, Mark Bagley, Mark Papania

Keywords(s): AB1XXX, AB3FXX, AB3GXX, ABXXXX, Agents, AXXXXX, BACTERIA, Bacterial, BACTERIAL VACCINES, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, Child safety device, CHILDHOOD, Children, DB1XXX, DB2XXX, DB3XXX, DB4AXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DC2XXX, DC3XXX, DC4XXX, DC5XXX, DC6XXX, DCXXXX, Delivery, delivery system, DEVELOPED, DEVELOPING, DEVICE, Devices, Disposable, DISPOSAL, Dry, DXXXXX, Field, Field-usable, FUNGAL, Intranasal, MEASLES, NASAL, Needle, OID-NCIRD-DVD, Portable, POWDER, Prevention, respiratory, SAFETY, SELF-ADMINISTRATION, Single-use, System, therapeutic delivery, treatment, VACCINATION, Vaccinations, VACCINE DELIVERY, vaccines, VBXXXX, viral vaccine, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WKXXXX, WMXXXX, XDXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Medical Devices, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Non-Medical Devices, Application > Consumer Products, Application > Therapeutics

HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct

CDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal...

Published: 7/25/2024 | Inventor(s): Sherry Owen, Renu Lal

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructs, DB4AXX, DB4XXX, DBXXXX, DC1XXX, DC5AXX, DC5XXX, DCXXXX, HIV-1, Immunogenic, Methods, Multi-clade, MULTIVALENT, OID-NCHHSTP-DHPSE, Their

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Therapeutics

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER)...

Published: 7/25/2024 | Inventor(s): John Mascola, Leo Laub, Jinghe Huang, Peter Kwong, Gilad Ofek, Jiang Zhu, Gary Nabel, Ivelin Georgiev, Yongping Yang, Rebecca Rudicell, Mark Connors

Keywords(s): antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, Application > Vaccines

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...

Published: 7/25/2024 | Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner

Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology

The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection

This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease. a4b7...

Published: 7/25/2024 | Inventor(s): Anthony Fauci, Claudia Cicala, Diana Goode, James Arthos

Keywords(s): ANTAGONISTS, BBXXXX, BETWEEN, DB4AXX, DB4XXX, DBXXXX, Direct, DXXXXX, gp120, HIV, INTERACTION, Intregrin, VLXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Viral Entry or Replication Inhibitors

The Tec family of tyrosine kinases, consisting of five family members Tec, Btk, Itk, Rlk, and BMX, are key regulators of signaling pathways of T lymphocytes. Many existing antiviral therapies rely on inhibition of viral replication, which leads to emergence or selection of resistant viruses. The current technology provides an alternative method for...

Published: 4/8/2024 | Inventor(s): Julie Readinger

Keywords(s): BBXXXX, DB4AXX, DBXXXX, DXXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

1 2